RxDoctor Payments Data

Maria Rojas-Bita, MD

Family Medicine · Grand Island, NENPI 1467942649

Payments from drug & device makers

$682in general payments, 2019–2025

Across 39 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$103
  • Otsuka America Pharmaceutical, Inc.$103
  • Lilly USA, LLC$94
  • Johnson & Johnson$56
  • Novo Nordisk$50
  • Abbott$48
  • plus $229 from 12 others

What the payments were for

  • Food & beverage$682100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$682 in reported general payments places this provider in the 55th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$50,793
Medicare patients
166
Services billed
1,073

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide72$73,111
FarxigaDapagliflozin Propanediol62$62,571
JanuviaSitagliptin Phosphate40$25,784
JardianceEmpagliflozin13$21,737
XareltoRivaroxaban40$20,039
OzempicSemaglutide15$18,505
LinzessLinaclotide21$17,195
KerendiaFinerenone14$13,004
EliquisApixaban18$12,320
MyrbetriqMirabegron20$11,020
ArexvyRsvpref3 Antigen/As01e/Pf29$8,960
Insulin Lispro Kwikpen U-100Insulin Lispro14$5,459
ShingrixVaricella-Zoster Ge/As01b/Pf21$4,562
Levemir FlexpenInsulin Detemir14$4,359
Novolog FlexpenInsulin Aspart12$2,470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$94$73,11172 claims
AstraZenecaFarxiga$27$62,57162 claims
MerckJanuvia$22$25,78440 claims
Johnson & JohnsonXarelto$56$20,03940 claims
Novo NordiskOzempic$50$18,50515 claims
AbbVieLinzess$103$17,19521 claims
GSKArexvy, Shingrix$16$13,52250 claims
BayerKerendia$13$13,00414 claims
PfizerEliquis$14$12,32018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Grand Island

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →